Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists;Effektivität der antiviralen behandlung von patienten mit chronischer hepatitis C in der gastroenterologischen facharztpraxis

Zeitschrift fur Gastroenterologie

Volumn 44, Issue 1, 2006, Pages 25-31

  Hofmann, W P ^b   Bock, H ^b   Weber, C ^b   Tacke, W ^b   Pfaff, R ^b   Kihn, R ^b   Moog, C ^b   Kellner, H U ^b   Schofer M ^b   Frick, B ^b   Berg, P ^b   Rambow, A ^b   Friedrich Rust, M ^b   Herrmann, E ^b   Sarrazin, C ^b   Zeuzem, Stefan ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b NONE

Author keywords

Hepatitis C; Liver; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GENOTYPE; GERMANY; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIVATE PRACTICE; RELAPSE; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DRUG COMBINATIONS; FEMALE; GASTROENTEROLOGY; GERMANY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PRIVATE PRACTICE; PROGNOSIS; REMOTE CONSULTATION; RIBAVIRIN; TREATMENT OUTCOME;

EID: 31944449692     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858960     Document Type: Article

References (22)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52
2. Zeuzem S, Roth WK, Herrmann G. [Viral hepatitis C]. Z Gastroenterol 1995;33:117-132
3. Gurtler L. [Hepatitis C in Germany. More than 5000 new infections annually]. MMW Fortschr Med 2002;144:26-28
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2 b plus ribavirin compared with interferon alfa-2 b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965
5. Fried MW, Shiftman ML, Reddy KR et al. Peginterferon alfa-2 a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: 975-982
6. Hadziyannis SJ, Sette H, Jr et al. Peginterferon-alpha2 a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140: 346-355
7. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2 b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40: 993-999
8. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004;140:370-381
9. Pawlotsky JM. Treating hepatitis C in "difficult-to-treat" patients. N Engl J Med 2004;351:422-423
10. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1 -infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069
11. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37: 600-609
12. Davis GL, Wong JB, McHutchison JG et al. Early virologic response to treatment with peginterferon alfa-2 b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652
13. Gross CP, Mallory R, Heiat A et al. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med 2002;137:10-16
14. Hirth RA, Fendrick AM, Chernew ME. Specialist and generalist physicians' adoption of antibiotic therapy to eradicate Helicobacter pylori infection. Med Care 1996;34:1199-1204
15. European Association for the Study of the Liver. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. J Hepatol 1999;30:956-961
16. Fleig WE, Krummenerl P, Lesske J et al. [Diagnosis, progression and therapy of hepatitis C virus infection as well as viral infection in children and adolescents-results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and and in cooperation with the Hepatitis Competence Network]. Z Gastroenterol 2004;42:703-704
17. Strader DB, Wright T, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171
18. Freemantle N, Harvey EL, Wolf F et al. Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2000; CD000172
19. Freemantle N. Implementation strategies. Fam Pract 2000;17 Suppl 1: S7-10
20. Gerlach FM, Beyer M, Szecsenyi J et al. Leitlinien in Klinik und Praxis. Dt Ärzteblatt 1998;95:A1014-1021
21. Shehab TM, Fontana RJ, Oberhelman K et al. Effectiveness of interferon alpha-2 b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol 2004;2:425-431
22. Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol 2005;42:266-274